AMG-820
- Generic Name
- AMG-820
A Study of AMG 820 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsCancerOncologyTumorsAdvanced MalignancyOncology Patients
- Interventions
- First Posted Date
- 2011-09-30
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01444404
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath